Differential effect of the 17 beta-aminoestrogens prolame, butolame and pentolame in anxiety and depression models in rats

摘要

Estrogens of clinical use produce consistent antidepressant-and anxiolytic-like effects in animal models of men-opause. Regulation of the hypothalamic-pituitary-adrenal (HPA) or stress axis, has been proposed as a pathway through which estrogens improve affective-like behaviors. Anticoagulant 17 beta-aminoestrogens (17 beta-AEs) butolame and pentolame mimic some effects of estradiol (E-2), i.e., on female rodent sexual behavior, with opposite actions on coagulation. However, their psychoactive actions have not been explored. On the basis of similitude with E-2's effects, we hypothesized that these 17 beta-AEs would induce anxiolytic- and antidepressant-like effects, which would be reflected in a reduction of activity in the HPA axis. In ovariectomized female rats, chronic treatment with prolame (60 mu g/kg), butolame (65 mu g/kg) and pentolame (70 mu g/kg) reduced anxiety-like behavior in the elevated plus maze (evidenced by an increase in time in open arms, E-2 (40 mu g/kg) + 176%; prolame + 201%; butolame, +237%; and pentolame + 295%, in comparison to the control vehicle group 100%). Pentolame also decreased significantly anxiety-like behavior in the burying behavior test. Prolame and E-2 produced a significantly antidepressant-like action, which was not induced by butolame and pentolame. Behavioral effects of 17 beta AEs (and E-2) on anxiety and depression did not follow the same pattern than corticosterone or E-2 levels; they also were associated to changes in locomotor activity, evaluated by the open field test. These results constitute the first evidence of specific and selective actions of butolame and pentolame as anxiolytics for females with a hypoestrogenic condition. Results also confirm the potential of prolame as an antidepressant steroid with equivalent actions to E-2. Psychoactive properties of 17 beta-AEs in combinations with reduced adverse effects on coagulation, suggest that 17 beta-AEs may be a good alternative replacement therapy for women with symptoms associated with menopause. (C) 2015 Elsevier Inc. All rights reserved.